RUNX2 and neoplasm: Our previous findings based on analyses in PCCs derived from matched tumor samples obtained prior to, and following CT treatment from two serous EOC patients, were suggestive for RUNX2 overexpression in advanced (metastatic) EOC, which might be due to epigenetic mechanisms, associated with DNA hypomethylation of its putative promoter region [9].